Switch theme
Sign up to access all valuation multiples
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
1998
500
LTM Revenue $768M
Last FY EBITDA $138M
$7.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Corcept Therapeutics has a last 12-month revenue (LTM) of $768M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Corcept Therapeutics achieved revenue of $675M and an EBITDA of $138M.
Corcept Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Corcept Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $768M | XXX | $675M | XXX | XXX | XXX |
| Gross Profit | $756M | XXX | $664M | XXX | XXX | XXX |
| Gross Margin | 98% | XXX | 98% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $138M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 20% | XXX | XXX | XXX |
| EBIT | $151M | XXX | $137M | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 20% | XXX | XXX | XXX |
| Net Profit | $152M | XXX | $141M | XXX | XXX | XXX |
| Net Margin | 20% | XXX | 21% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Corcept Therapeutics's stock price is $77.
Corcept Therapeutics has current market cap of $8.2B, and EV of $7.9B.
See Corcept Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.9B | $8.2B | XXX | XXX | XXX | XXX | $1.29 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Corcept Therapeutics has market cap of $8.2B and EV of $7.9B.
Corcept Therapeutics's trades at 11.7x EV/Revenue multiple, and 57.1x EV/EBITDA.
Equity research analysts estimate Corcept Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Corcept Therapeutics has a P/E ratio of 54.0x.
See valuation multiples for Corcept Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8.2B | XXX | $8.2B | XXX | XXX | XXX |
| EV (current) | $7.9B | XXX | $7.9B | XXX | XXX | XXX |
| EV/Revenue | 10.3x | XXX | 11.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 57.1x | XXX | XXX | XXX |
| EV/EBIT | 52.4x | XXX | 57.7x | XXX | XXX | XXX |
| EV/Gross Profit | 10.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 54.0x | XXX | 58.2x | XXX | XXX | XXX |
| EV/FCF | 38.2x | XXX | 40.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCorcept Therapeutics's last 12 month revenue growth is 34%
Corcept Therapeutics's revenue per employee in the last FY averaged $1.4M, while opex per employee averaged $1.1M for the same period.
Corcept Therapeutics's rule of 40 is 57% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Corcept Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Corcept Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 34% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | 36% | XXX | XXX | XXX |
| Rule of 40 | 57% | XXX | 55% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 37% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 78% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Corcept Therapeutics acquired XXX companies to date.
Last acquisition by Corcept Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Corcept Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Corcept Therapeutics founded? | Corcept Therapeutics was founded in 1998. |
| Where is Corcept Therapeutics headquartered? | Corcept Therapeutics is headquartered in United States of America. |
| How many employees does Corcept Therapeutics have? | As of today, Corcept Therapeutics has 500 employees. |
| Who is the CEO of Corcept Therapeutics? | Corcept Therapeutics's CEO is Dr. Joseph K. Belanoff, M.D.. |
| Is Corcept Therapeutics publicy listed? | Yes, Corcept Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Corcept Therapeutics? | Corcept Therapeutics trades under CORT ticker. |
| When did Corcept Therapeutics go public? | Corcept Therapeutics went public in 2004. |
| Who are competitors of Corcept Therapeutics? | Similar companies to Corcept Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Corcept Therapeutics? | Corcept Therapeutics's current market cap is $8.2B |
| What is the current revenue of Corcept Therapeutics? | Corcept Therapeutics's last 12 months revenue is $768M. |
| What is the current revenue growth of Corcept Therapeutics? | Corcept Therapeutics revenue growth (NTM/LTM) is 34%. |
| What is the current EV/Revenue multiple of Corcept Therapeutics? | Current revenue multiple of Corcept Therapeutics is 10.3x. |
| Is Corcept Therapeutics profitable? | Yes, Corcept Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current FCF of Corcept Therapeutics? | Corcept Therapeutics's last 12 months FCF is $207M. |
| What is Corcept Therapeutics's FCF margin? | Corcept Therapeutics's last 12 months FCF margin is 27%. |
| What is the current EV/FCF multiple of Corcept Therapeutics? | Current FCF multiple of Corcept Therapeutics is 38.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
